Yeshurun D, Dakak N, Khoury K, Daher E
Harefuah. 1989 Mar 1;116(5):261-3.
The second generation fibric acid derivative, bezafibrate (Bezalip, Norlip) is widely used as a hypolipemic agent throughout Europe and Israel. Its side-effects are well documented, and include myositis, which is considered very rare. We report a 55-year-old diabetic woman with hypertension who had mild renal dysfunction (creatinine 2.0 mg/dl) who received 400 mg/d bezafibrate because of combined (Type IIb) hyperlipoproteinemia. She developed acute myositis, with extreme muscle weakness, pain and CPK levels of up to 3500 units. On discontinuation of the drug all clinical and biochemical features ceased and complete cure followed. No other symptoms have appeared during 2 years of followup. The few reports of such cases in the German literature point to a greater prevalence of myositis in those with renal dysfunction. Early diagnosis of bezafibrate-induced myositis is crucial, a discontinuation of the drug results in cure.
第二代纤维酸衍生物苯扎贝特（Bezalip、Norlip）在欧洲和以色列被广泛用作降血脂药物。其副作用已有充分记录，包括被认为非常罕见的肌炎。我们报告一名55岁患有高血压的糖尿病女性，有轻度肾功能不全（肌酐2.0mg/dl），因混合型（IIb型）高脂蛋白血症接受400mg/d苯扎贝特治疗。她出现了急性肌炎，伴有极度肌肉无力、疼痛，肌酸磷酸激酶水平高达3500单位。停药后所有临床和生化特征均消失，并完全治愈。在2年的随访中未出现其他症状。德国文献中关于此类病例的少数报告指出，肾功能不全患者中肌炎的患病率更高。苯扎贝特诱发肌炎的早期诊断至关重要，停药可治愈。
